Senores Pharmaceuticals Reports Strong FY26 Growth

Senores Pharmaceuticals announced impressive financial results for the fiscal year 2026, with revenue reaching INR 664 crore, a 62% increase from the previous year. Profit After Tax (PAT) saw an even more significant surge of 108%, totaling INR 122 crore for the year ending March 2026.

Key Financial Highlights

The company's financial report, released on May 14, 2026, revealed consolidated revenue of INR 664 crore, up 62% year-over-year. PAT grew by 108% to INR 122 crore. Senores Pharmaceuticals emphasized its strong performance in regulated markets, where revenue climbed 83% to INR 427 crore, driven by product portfolio expansion and successful market entries. The company's Abbreviated New Drug Application (ANDA) portfolio expanded to 51 approved applications by March 2026, up from 22 the previous year, with 20 now commercially launched.

Strategic Acquisitions Fuel Growth

Strategic acquisitions were central to Senores Pharmaceuticals' expansion strategy. The company acquired a 75% stake in Apnar Pharma, a USFDA-approved facility, and acquired Zoraya Pharmaceuticals. These moves are designed to strengthen the company's marketing and distribution capabilities within the United States.

Future Outlook and Strategy

Senores Pharmaceuticals is preparing to launch 30 more approved ANDAs over the next 6-8 quarters. Capital expenditure of approximately INR 200 crore is planned for FY27, focusing on sterile manufacturing development. Management's long-term vision is to build a substantial U.S. business, targeting revenues between INR 2,500 to INR 3,000 crore within the next 3-5 years.

Potential Challenges Ahead

Despite the positive performance, the company faces some challenges. The Apnar acquisition led to a significant increase in the working capital cycle to 187 days. Acquisition-related expenses have temporarily reduced blended margins by about 100 basis points. Delays in operational projects, such as the Atlanta OSD facility's fourth line expansion, and a more conservative revenue forecast for FY27 due to external factors like shipping disruptions and U.S. inflation, are also areas to monitor.

Key Metrics and Investor Watchpoints

Investors will closely watch the successful integration of Apnar Pharma and Zoraya Pharmaceuticals. The company's ability to roll out its remaining approved ANDAs and advance its sterile manufacturing capabilities will be crucial. Monitoring the working capital cycle's normalization and tracking the actual revenue growth against the FY27 guidance of 30-40% will be key indicators for future performance.